CA3188019A1 - Cardiovascular health-promoting composition - Google Patents
Cardiovascular health-promoting compositionInfo
- Publication number
- CA3188019A1 CA3188019A1 CA3188019A CA3188019A CA3188019A1 CA 3188019 A1 CA3188019 A1 CA 3188019A1 CA 3188019 A CA3188019 A CA 3188019A CA 3188019 A CA3188019 A CA 3188019A CA 3188019 A1 CA3188019 A1 CA 3188019A1
- Authority
- CA
- Canada
- Prior art keywords
- lactobacillus
- composition
- stable composition
- long
- term storage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 230000002526 effect on cardiovascular system Effects 0.000 title description 3
- 240000004482 Withania somnifera Species 0.000 claims abstract description 37
- 235000001978 Withania somnifera Nutrition 0.000 claims abstract description 36
- 239000009405 Ashwagandha Substances 0.000 claims abstract description 34
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 27
- 235000002378 plant sterols Nutrition 0.000 claims abstract description 26
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 23
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 21
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 21
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 20
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 18
- 241000186660 Lactobacillus Species 0.000 claims description 19
- 229940039696 lactobacillus Drugs 0.000 claims description 16
- 239000006041 probiotic Substances 0.000 claims description 16
- 235000018291 probiotics Nutrition 0.000 claims description 16
- 230000007774 longterm Effects 0.000 claims description 15
- 238000003860 storage Methods 0.000 claims description 14
- 230000000529 probiotic effect Effects 0.000 claims description 10
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 9
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 9
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 9
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 9
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 9
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 9
- 235000000431 campesterol Nutrition 0.000 claims description 9
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 9
- 229950005143 sitosterol Drugs 0.000 claims description 9
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 9
- 235000016831 stigmasterol Nutrition 0.000 claims description 9
- 229940032091 stigmasterol Drugs 0.000 claims description 9
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 9
- 244000005700 microbiome Species 0.000 claims description 8
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 7
- 230000001332 colony forming effect Effects 0.000 claims description 5
- BSCMKVMJAHJNJW-UHFFFAOYSA-L 3-[2-carboxyethyl(dichloro)stannyl]propanoic acid Chemical compound OC(=O)CC[Sn](Cl)(Cl)CCC(O)=O BSCMKVMJAHJNJW-UHFFFAOYSA-L 0.000 claims description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 239000004615 ingredient Substances 0.000 abstract description 4
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 2
- 230000036996 cardiovascular health Effects 0.000 abstract description 2
- 244000005709 gut microbiome Species 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 27
- 238000009472 formulation Methods 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 229940068065 phytosterols Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PQZVBIJEPVKNOZ-PCLZMVHQSA-N (2R)-2-[(1S)-1-hydroxy-1-[(5R,6R,8R,9S,10R,13S,14R,17S)-5,6,14,17-tetrahydroxy-10,13-dimethyl-1-oxo-6,7,8,9,11,12,15,16-octahydro-4H-cyclopenta[a]phenanthren-17-yl]ethyl]-4,5-dimethyl-2,3-dihydropyran-6-one Chemical class C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@]1(O)[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=CC[C@]4(O)[C@H](O)C[C@H]3[C@]2(O)CC1 PQZVBIJEPVKNOZ-PCLZMVHQSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 108010000231 Choloylglycine hydrolase Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 235000000340 Solanum pseudocapsicum Nutrition 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- JAVFSUSPBIUPLW-QEWGJZFKSA-N Withanolide Natural products O=C1[C@@H](C)[C@H](C)C[C@H]([C@@H](C)[C@@H]2[C@@]3(C)[C@H]([C@@H]4[C@@H]([C@]5(C)[C@@H](CC4)CCCC5)CC3)CC2)O1 JAVFSUSPBIUPLW-QEWGJZFKSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000033227 intestinal cholesterol absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- SASUFNRGCZMRFD-JCUIILOWSA-N withanolide D Chemical compound C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-JCUIILOWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
Described herein is a composition comprising a unique and novel combination of natural ingredients supporting cardiovascular health by contributing to healthy serum cholesterol levels while also reducing CRP and IL-6 cytokine levels.
Furthermore, the composition promotes the development of a healthy or healthier gut microbiome.
The composition comprises 10%-70% Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof; 2%-86% plant sterols; and 4%-88% Ashwagandha root powder.
Furthermore, the composition promotes the development of a healthy or healthier gut microbiome.
The composition comprises 10%-70% Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof; 2%-86% plant sterols; and 4%-88% Ashwagandha root powder.
Description
CARDIOVASCULAR HEALTH-PROMOTING COMPOSITION
BACKGROUND OF THE INVENTION
Over 35 million Americans alone take statin drugs to reduce cholesterol, yet some people are still unable to get their cholesterol under control, and heart disease remains the leading killer of Americans.
Probiotics are beneficial bacteria, two strains of which, L. plantarum and L.
reuteri have been demonstrated to reduce LDL cholesterol levels and reduce C-reactive protein (CRP). For example, studies have shown that these probiotics promote favorable outcomes in hypercholesterolemic and/or hyperlipidemic patients, including statistically significant reductions in LDL level and cardiovascular events.
Plant sterols are plant components that have a chemical structure similar to cholesterol except for the addition of an extra methyl or ethyl group.
However, despite the structural similarity, plant sterol absorption in humans is considerably less than that of cholesterol. In fact, there is evidence that plant sterols reduce cholesterol absorption and thus reduce circulating levels of cholesterol.
Withania somnifera, also known as ashwagandha or winter cherry is sold in many countries as a medicinal herb or as a dietary supplement. Typically, ashwagandha is prepared as a root powder. Ashwagandha is used in traditional medicines to decrease inflammation, cortisol-related anxiety and cholesterol.
SUMMARY OF THE INVENTION
According to a first aspect of the invention, there is provided a long-term storage stable composition comprising:
10%-70% Lactobacillus, selected from the group consisting of: Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
BACKGROUND OF THE INVENTION
Over 35 million Americans alone take statin drugs to reduce cholesterol, yet some people are still unable to get their cholesterol under control, and heart disease remains the leading killer of Americans.
Probiotics are beneficial bacteria, two strains of which, L. plantarum and L.
reuteri have been demonstrated to reduce LDL cholesterol levels and reduce C-reactive protein (CRP). For example, studies have shown that these probiotics promote favorable outcomes in hypercholesterolemic and/or hyperlipidemic patients, including statistically significant reductions in LDL level and cardiovascular events.
Plant sterols are plant components that have a chemical structure similar to cholesterol except for the addition of an extra methyl or ethyl group.
However, despite the structural similarity, plant sterol absorption in humans is considerably less than that of cholesterol. In fact, there is evidence that plant sterols reduce cholesterol absorption and thus reduce circulating levels of cholesterol.
Withania somnifera, also known as ashwagandha or winter cherry is sold in many countries as a medicinal herb or as a dietary supplement. Typically, ashwagandha is prepared as a root powder. Ashwagandha is used in traditional medicines to decrease inflammation, cortisol-related anxiety and cholesterol.
SUMMARY OF THE INVENTION
According to a first aspect of the invention, there is provided a long-term storage stable composition comprising:
10%-70% Lactobacillus, selected from the group consisting of: Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
2%-86% plant sterols; and 4%-88% Ashwagandha root powder.
In some embodiments of the invention, the composition is storage-stable for at least 6 months.
In some embodiments, the probiotic microorganism is a mixture of Lactobacillus plantarum and Lactobacillus reuteri.
Date Recue/Date Received 2023-01-24 In some embodiments, the Lactobacillus plantarum is one or more of CECT 7527, CECT 7528 and CETC 7529.
In some embodiments, the Lactobacillus plantarum and/or Lactobacillus reuteri is added at 1X106, 1X107, 118, 1X109, 1X1010 or more colony forming units (CFU) per gram.
In some embodiments, the composition has at least 1X106 CFU per gram after 6 months.
In some embodiments, the plant sterols are a mixture of P-sitosterol, campesterol and stigmasterol.
In some embodiments, the mixture of plant sterols is at least 35% p-sitosterol, at least 20% campesterol and at least 10% stigmasterol.
In some embodiments, the mixture of plant sterols is at least 40% P-sitosterol, at least 26% campesterol and at least 18% stigmasterol.
In some embodiments, the storage-stable composition comprises (a) 100 mg Lactobacillus plantarum, Lactobacillus reuteri or mixtures thereof; (b) 50 mg Ashwagandha root powder; and (c) 370 mg plant sterols.
According to another aspect of the invention, there is provided a method of treating or ameliorating one or more symptoms of hypercholesterolemia and/or hyperlipidemia in an individual suffering from hypercholesterolemia and/or hyperlipidemia and/or diagnosed with high LDL cholersterol, said method comprising:
administering to the individual an effective amount of a composition comprising:
10%-70% Lactobacillus, selected from the group consisting of:
Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
2%-86% plant sterols; and 4%-88% Ashwagandha root powder.
According to another aspect of the invention, there is provided use of the composition as described above for treating, reducing the severity of or ameliorating hypercholesterolemia and/or hyperlipidemia.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the Date Recue/Date Received 2023-01-24
In some embodiments of the invention, the composition is storage-stable for at least 6 months.
In some embodiments, the probiotic microorganism is a mixture of Lactobacillus plantarum and Lactobacillus reuteri.
Date Recue/Date Received 2023-01-24 In some embodiments, the Lactobacillus plantarum is one or more of CECT 7527, CECT 7528 and CETC 7529.
In some embodiments, the Lactobacillus plantarum and/or Lactobacillus reuteri is added at 1X106, 1X107, 118, 1X109, 1X1010 or more colony forming units (CFU) per gram.
In some embodiments, the composition has at least 1X106 CFU per gram after 6 months.
In some embodiments, the plant sterols are a mixture of P-sitosterol, campesterol and stigmasterol.
In some embodiments, the mixture of plant sterols is at least 35% p-sitosterol, at least 20% campesterol and at least 10% stigmasterol.
In some embodiments, the mixture of plant sterols is at least 40% P-sitosterol, at least 26% campesterol and at least 18% stigmasterol.
In some embodiments, the storage-stable composition comprises (a) 100 mg Lactobacillus plantarum, Lactobacillus reuteri or mixtures thereof; (b) 50 mg Ashwagandha root powder; and (c) 370 mg plant sterols.
According to another aspect of the invention, there is provided a method of treating or ameliorating one or more symptoms of hypercholesterolemia and/or hyperlipidemia in an individual suffering from hypercholesterolemia and/or hyperlipidemia and/or diagnosed with high LDL cholersterol, said method comprising:
administering to the individual an effective amount of a composition comprising:
10%-70% Lactobacillus, selected from the group consisting of:
Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
2%-86% plant sterols; and 4%-88% Ashwagandha root powder.
According to another aspect of the invention, there is provided use of the composition as described above for treating, reducing the severity of or ameliorating hypercholesterolemia and/or hyperlipidemia.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the Date Recue/Date Received 2023-01-24
3 invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.
Described herein is a composition comprising a unique and novel combination of natural ingredients supporting cardiovascular health by contributing to healthy serum cholesterol levels while also reducing CRP and 1L-6 cytokine levels.
Furthermore, the composition promotes the development of a healthy or healthier gut rnicrobiome.
According to the invention, there is provided a storage-stable composition comprising (a) a probiotic microorganism; (b) an Ashwagandha extract; and (c) plant sterols.
In some embodiments of the invention, the probiotic microorganism is a Lactobacillus, for example, Lactobacillus plantarum or Lactobacillus reuteri.
In some embodiments of the invention, probiotic microorganism is a mixture of Lactobacillus plantarum and Lactobacillus reuteri.
In some embodiments of the invention, the Lactobacillus plantarum is one or more of CECT 7527, CECT 7528 and CETC 7529.
As is known by those of skill in the art, at least some strains of L.
plantarum reduce systolic blood pressure; and leptin, LDL cholesterol and fibrinogen concentrations (Naruszewicz et al., 2002, Am J Clin Nutrition 76:1249-1255). Addiitonally, some strains of Lactobacillus have been shown to be anti-atherogenetic and/or to reduce the arteriosclerotic index of patients (Ding et al., 2017, Oncotarget 8: 59915-59928).
Furthermore, Lactobacilli are associated with the production of short chain fatty acids, which are associated with better colon health.
In some embodiments of the invention, the Lactobacillus plantarum and/or Lactobacillus reuteri is added at 1X106, 1X107, 1X108, 1X109, 1X101 or more colony forming units (CFU) per gram.
In some embodiments of the invention, the Ashwagandha is a root powder of Ashwagandha. It is noted that such root powder extracts are available commercially. For example, in some methods, the Ashwagandha roots are cut off or otherwise separated from the Ashwagandha plant, cleaned to remove any contaminants, infected roots or adhered dust or the like, pulverized and then separated over size 10 MESH to 30 MESH. It Is noted that such preparations of Ashwagandha root powder are known in the art and are Date Recue/Date Received 2023-01-24
Described herein is a composition comprising a unique and novel combination of natural ingredients supporting cardiovascular health by contributing to healthy serum cholesterol levels while also reducing CRP and 1L-6 cytokine levels.
Furthermore, the composition promotes the development of a healthy or healthier gut rnicrobiome.
According to the invention, there is provided a storage-stable composition comprising (a) a probiotic microorganism; (b) an Ashwagandha extract; and (c) plant sterols.
In some embodiments of the invention, the probiotic microorganism is a Lactobacillus, for example, Lactobacillus plantarum or Lactobacillus reuteri.
In some embodiments of the invention, probiotic microorganism is a mixture of Lactobacillus plantarum and Lactobacillus reuteri.
In some embodiments of the invention, the Lactobacillus plantarum is one or more of CECT 7527, CECT 7528 and CETC 7529.
As is known by those of skill in the art, at least some strains of L.
plantarum reduce systolic blood pressure; and leptin, LDL cholesterol and fibrinogen concentrations (Naruszewicz et al., 2002, Am J Clin Nutrition 76:1249-1255). Addiitonally, some strains of Lactobacillus have been shown to be anti-atherogenetic and/or to reduce the arteriosclerotic index of patients (Ding et al., 2017, Oncotarget 8: 59915-59928).
Furthermore, Lactobacilli are associated with the production of short chain fatty acids, which are associated with better colon health.
In some embodiments of the invention, the Lactobacillus plantarum and/or Lactobacillus reuteri is added at 1X106, 1X107, 1X108, 1X109, 1X101 or more colony forming units (CFU) per gram.
In some embodiments of the invention, the Ashwagandha is a root powder of Ashwagandha. It is noted that such root powder extracts are available commercially. For example, in some methods, the Ashwagandha roots are cut off or otherwise separated from the Ashwagandha plant, cleaned to remove any contaminants, infected roots or adhered dust or the like, pulverized and then separated over size 10 MESH to 30 MESH. It Is noted that such preparations of Ashwagandha root powder are known in the art and are Date Recue/Date Received 2023-01-24
4 commercially available. For example, such commercial preparations are typically classified by activity, for example, Ashwagandha Root PE 40:1 std. 5% by HPLC gives 5%
active withanolides.
Similarly, there are several commercially available mixtures of plant sterols, for example, mixtures that have for example 8-sitosterol, campesterol or stigmasterol as their main ingredient. In some embodiments of the invention, the plant sterols or phytosterols are a mixture of p-sitosterol, campesterol and stigmasterol, for example, a mixture of plant sterols that is at least 35% for example at least 40% f3-sitosterol, at least 20%, for example, at least 25% or at least 26% campesterol and at least 10%, for example, at least 15% or at least 18% stigmasterol.
In some embodiments of the invention, the storage-stable composition comprises:
10%-70% probiotic microorganism, selected from the group consisting of:
Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
2%-86% plant sterols;
4%-88% Ashwagandha root powder.
In some embodiments of the invention, the long-term storage stable composition comprises:
10-25% Lactobacillus, selected from the group consisting of: Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
50-86% plant sterols; and 4-20% Ashwagandha root powder.
In some embodiments of the invention, the probiotic microorganism, the plant sterols and the Ashwagandha root powder are mixed together as dry powders and distributed to capsules, for example, 100 mg capsules, 150 mg capsules, 200 mg capsule, 250 mg capsules, 300 mg capsules, 350 mg capsule, 400 mg capsules, 450 mg capsules, 500 mg capsules, 550 mg capsules, 600 mg capsules, 650 mg capsules, 700 mg capsules or 750 mg capsules.
In some embodiments of the invention, non-medicinal additives such as for example magnesium stearate and/or microcrystalline cellulose and the like may be added to the mixture prior to distribution into capsules.
In some embodiments, suitable pharmaceutically acceptable excipients may be added to the storage-stable composition.
Date Recue/Date Received 2023-01-24
active withanolides.
Similarly, there are several commercially available mixtures of plant sterols, for example, mixtures that have for example 8-sitosterol, campesterol or stigmasterol as their main ingredient. In some embodiments of the invention, the plant sterols or phytosterols are a mixture of p-sitosterol, campesterol and stigmasterol, for example, a mixture of plant sterols that is at least 35% for example at least 40% f3-sitosterol, at least 20%, for example, at least 25% or at least 26% campesterol and at least 10%, for example, at least 15% or at least 18% stigmasterol.
In some embodiments of the invention, the storage-stable composition comprises:
10%-70% probiotic microorganism, selected from the group consisting of:
Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
2%-86% plant sterols;
4%-88% Ashwagandha root powder.
In some embodiments of the invention, the long-term storage stable composition comprises:
10-25% Lactobacillus, selected from the group consisting of: Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
50-86% plant sterols; and 4-20% Ashwagandha root powder.
In some embodiments of the invention, the probiotic microorganism, the plant sterols and the Ashwagandha root powder are mixed together as dry powders and distributed to capsules, for example, 100 mg capsules, 150 mg capsules, 200 mg capsule, 250 mg capsules, 300 mg capsules, 350 mg capsule, 400 mg capsules, 450 mg capsules, 500 mg capsules, 550 mg capsules, 600 mg capsules, 650 mg capsules, 700 mg capsules or 750 mg capsules.
In some embodiments of the invention, non-medicinal additives such as for example magnesium stearate and/or microcrystalline cellulose and the like may be added to the mixture prior to distribution into capsules.
In some embodiments, suitable pharmaceutically acceptable excipients may be added to the storage-stable composition.
Date Recue/Date Received 2023-01-24
5 In other embodiments of the invention, the storage-stable composition comprises (a) 50-125 mg Lactobacillus; (b) 20-100 mg Ashwagandha root powder; and (c) mg plant sterols. In these embodiments, the storage-stable composition is in a capsule that is at least 500 mg.
In some embodiments of the invention, the storage-stable composition comprises (a) 100 mg Lactobacillus; (b) 50 mg Ashwagandha root powder; and (c) 370 mg plant sterols. In these embodiments, the storage-stable composition is in a capsule that is at least 500 mg.
For example, in these embodiments, the composition may be in the form of a 520 mg capsule, a 525 mg capsule, a 550 mg capsule or a 600 mg capsule.
In some embodiments, the capsules are sprayed with an enteric coating.
However, in other embodiments, the capsule may already be impregnated with a suitable coating prior to distribution of the mixture therein. As will be appreciated by one of skill in the art, a suitable coating or an enteric coating is a coating such that when the coated capsule .. reaches the alkaline environment of the lower bowel, the coating on the capsule dissolves so that the contents of the capsule are released.
In some embodiments of the invention, the composition is administered daily for a period of at least 12 weeks.
In some embodiments of the invention, the composition is administered to an individual who is also being administered statins, for example, a statin drug on a dosage regimen or schedule.
The statin may be a statin drug selected from the group consisting of atorvastatin, Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
In some embodiments of the invention, there is provided use of the composition of the invention for treating, reducing the severity of or ameliorating hypercholesterolemia.
According to another embodiment of the invention, there is provided a method of treating, ameliorating and/or reducing the severity of one or more symptoms associated with hypercholesterolemia and/or hyperlipidemia, for example, high LDL levels, chest pain and/or high blood pressure, comprising administering an effective amount of the composition of the invention to an individual in need of such treatment, for example, an individual suffering from or diagnosed with high LDL cholesterol and/or hypercholesterolemia.
Date Recue/Date Received 2023-01-24
In some embodiments of the invention, the storage-stable composition comprises (a) 100 mg Lactobacillus; (b) 50 mg Ashwagandha root powder; and (c) 370 mg plant sterols. In these embodiments, the storage-stable composition is in a capsule that is at least 500 mg.
For example, in these embodiments, the composition may be in the form of a 520 mg capsule, a 525 mg capsule, a 550 mg capsule or a 600 mg capsule.
In some embodiments, the capsules are sprayed with an enteric coating.
However, in other embodiments, the capsule may already be impregnated with a suitable coating prior to distribution of the mixture therein. As will be appreciated by one of skill in the art, a suitable coating or an enteric coating is a coating such that when the coated capsule .. reaches the alkaline environment of the lower bowel, the coating on the capsule dissolves so that the contents of the capsule are released.
In some embodiments of the invention, the composition is administered daily for a period of at least 12 weeks.
In some embodiments of the invention, the composition is administered to an individual who is also being administered statins, for example, a statin drug on a dosage regimen or schedule.
The statin may be a statin drug selected from the group consisting of atorvastatin, Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
In some embodiments of the invention, there is provided use of the composition of the invention for treating, reducing the severity of or ameliorating hypercholesterolemia.
According to another embodiment of the invention, there is provided a method of treating, ameliorating and/or reducing the severity of one or more symptoms associated with hypercholesterolemia and/or hyperlipidemia, for example, high LDL levels, chest pain and/or high blood pressure, comprising administering an effective amount of the composition of the invention to an individual in need of such treatment, for example, an individual suffering from or diagnosed with high LDL cholesterol and/or hypercholesterolemia.
Date Recue/Date Received 2023-01-24
6 As per above, the composition may be administered to the individual or patient or human patient on a dosage regimen of daily administration for at least 12 weeks.
It is noted that LDL cholesterol levels of 130-159 mg/dL are considered to be "borderline high", while levels of 160-189 mg/dL are considered to be "high"
and 190 mg/dL and above is considered to be very high.
As discussed herein, use of the composition and/or administration on a dosage regimen as discussed above will result in one or more of the following:
increased levels of gut or microbiome flora associated with good health, that is, a more favorable gut flora;
better intestinal/gastrointestinal health; reduction of LDL cholesterol levels; improvement of total cholesterol levels; increased energy; and reduction of fatigue.
As discussed herein, it is surprising that a mixture of: Lactobacillus plantarum and/or Lactobacillus reuteri with Ashwagandha root powder can retain activity for an extended period of time, for example, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months or at least 6 months or more.
Specifically, Ashwagandha is known to have antibacterial properties. For example, Bisht and Rawat demonstrated that Ashwagandha had anti-microbial properties against many Gram-positive bacteria, include methicillin resistant Staphylococcus and Enterococcus. Accordingly, one of skill in the art would have anticipated that a mixture of Ashwagandha root powder with a probiotic such as Lactobacillus plantarum and/or Lactobacillus reuteri would result in the antibacterial activity of the Ashwagandha root powder at least inhibiting growth of the probiotics.
Furthermore, probiotics have an extremely low water activity (Aw), for example, above 0.95. However, powders such as Ashwagandha root powder and phytosterols are typically produced at much lower Aw. As is known to those of skill in the art, blending powders having different Aw can affect the stability of such a mixture.
As discussed herein, "storage-stable" refers to the fact that, contrary to expectations, the number of Lactobacillus bacteria capable of forming colonies (colony-forming units) after 6 months was greater than 10% of the initial number of bacterial CFU
added to the composition. For example, if the initial bacterial CFU per gram added to the composition is 1X1019, after 6 months, the bacterial CFU per gram of the composition will be at least 1X109.
Date Recue/Date Received 2023-01-24
It is noted that LDL cholesterol levels of 130-159 mg/dL are considered to be "borderline high", while levels of 160-189 mg/dL are considered to be "high"
and 190 mg/dL and above is considered to be very high.
As discussed herein, use of the composition and/or administration on a dosage regimen as discussed above will result in one or more of the following:
increased levels of gut or microbiome flora associated with good health, that is, a more favorable gut flora;
better intestinal/gastrointestinal health; reduction of LDL cholesterol levels; improvement of total cholesterol levels; increased energy; and reduction of fatigue.
As discussed herein, it is surprising that a mixture of: Lactobacillus plantarum and/or Lactobacillus reuteri with Ashwagandha root powder can retain activity for an extended period of time, for example, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months or at least 6 months or more.
Specifically, Ashwagandha is known to have antibacterial properties. For example, Bisht and Rawat demonstrated that Ashwagandha had anti-microbial properties against many Gram-positive bacteria, include methicillin resistant Staphylococcus and Enterococcus. Accordingly, one of skill in the art would have anticipated that a mixture of Ashwagandha root powder with a probiotic such as Lactobacillus plantarum and/or Lactobacillus reuteri would result in the antibacterial activity of the Ashwagandha root powder at least inhibiting growth of the probiotics.
Furthermore, probiotics have an extremely low water activity (Aw), for example, above 0.95. However, powders such as Ashwagandha root powder and phytosterols are typically produced at much lower Aw. As is known to those of skill in the art, blending powders having different Aw can affect the stability of such a mixture.
As discussed herein, "storage-stable" refers to the fact that, contrary to expectations, the number of Lactobacillus bacteria capable of forming colonies (colony-forming units) after 6 months was greater than 10% of the initial number of bacterial CFU
added to the composition. For example, if the initial bacterial CFU per gram added to the composition is 1X1019, after 6 months, the bacterial CFU per gram of the composition will be at least 1X109.
Date Recue/Date Received 2023-01-24
7 While the probiotic strains L. planetarium and L. reuteri alone are efficacious ingredients capable of reducing LDL cholesterol, the addition of ashwagandha promotes reduction of other cardiovascular factors, such as, for example, triglyceride levels, CRP, IL-6, cortisol and body fat levels. As such, the surprising stability of the composition indicates that individuals in need thereof can be administered the composition and receive the benefits of the synergistic actions of the Ashwagandha root and the Lactobacillus as discussed herein. For example, the composition may be administered on a dosage regimen, for example, as a daily dosage, wherein "daily" does not necessarily mean "every day" but may mean for example 13 out of 14 days, 9 out of 10 days, 6 out of 7 days, 5 out 0f7 days, 3 out of 4 days or 2 out of 3 days.
As discussed herein, the mechanism responsible for the cholesterol-lowering effect of the composition is the inhibition of intestinal cholesterol absorption in the liver due to increased bile salt hydrolase activity. Specifically, this enzyme hydrolyzes bile salts into amino residues and free bile salts and suppresses bile acid reabsorption.
The invention will now be further explained and/or elucidated by way of example.
However, the invention is not necessarily limited to or by the examples.
EXAMPLE 1¨ LONG-TERM STABILITY TEST
Table 1 shows the results of a 6-month stability test.
Specifically, Formulation (A) is a control, comprising 100 mg of Lactobacillus and 400 mg of microcrystalline cellulose; Formulation (B) comprises 100 mg of Lactobacillus, 370 mg of phytosterols and 30 mg of microcrystalline cellulose; and Formulation (C) comprises 100 mg Lactobacillus, 370 mg phytosterols, 50 mg Ashwagandha root powder and 30 mg microcrystalline cellulose.
As indicated in Table 1, the source of Lactobacillus is FloradaptTM; however, other sources of suitable Lactobacillus strains may be used within the invention.
The respective mixtures were As can be seen, the composition of the three components (Formulation C) basically showed the same trend as probiotics alone (Formulation A). Specifically, the number of viable probiotic cells in the blend with the phytosterols and Ashwagandha trends similar to the control, so these ingredients are a compatible match. That is, each of the formulation preparations initially had 1.3-2.0 X101 bacterial cells. As can be seen in Table 1, at 1 Date Recue/Date Received 2023-01-24
As discussed herein, the mechanism responsible for the cholesterol-lowering effect of the composition is the inhibition of intestinal cholesterol absorption in the liver due to increased bile salt hydrolase activity. Specifically, this enzyme hydrolyzes bile salts into amino residues and free bile salts and suppresses bile acid reabsorption.
The invention will now be further explained and/or elucidated by way of example.
However, the invention is not necessarily limited to or by the examples.
EXAMPLE 1¨ LONG-TERM STABILITY TEST
Table 1 shows the results of a 6-month stability test.
Specifically, Formulation (A) is a control, comprising 100 mg of Lactobacillus and 400 mg of microcrystalline cellulose; Formulation (B) comprises 100 mg of Lactobacillus, 370 mg of phytosterols and 30 mg of microcrystalline cellulose; and Formulation (C) comprises 100 mg Lactobacillus, 370 mg phytosterols, 50 mg Ashwagandha root powder and 30 mg microcrystalline cellulose.
As indicated in Table 1, the source of Lactobacillus is FloradaptTM; however, other sources of suitable Lactobacillus strains may be used within the invention.
The respective mixtures were As can be seen, the composition of the three components (Formulation C) basically showed the same trend as probiotics alone (Formulation A). Specifically, the number of viable probiotic cells in the blend with the phytosterols and Ashwagandha trends similar to the control, so these ingredients are a compatible match. That is, each of the formulation preparations initially had 1.3-2.0 X101 bacterial cells. As can be seen in Table 1, at 1 Date Recue/Date Received 2023-01-24
8 month, 3 months and 6 months, the number of viable bacterial cells in each of the three formulation preparations are approximately equivalent, never dropping below 5X109 cfu per gram. This indicates that, contrary to expectations, the presence of the Ashwagandha root powder did not reduce the bacterial counts in formulation preparation (C) and there were no instability issues in either formulation preparation (B) or (C) despite the blending of powders having different Aw. As such, the number of Lactobacillus bacteria capable of forming colonies (colony-forming units) after 6 months was greater than 10% of the initial number of bacterial CFU added to the composition.
While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.
Date Recue/Date Received 2023-01-24
While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.
Date Recue/Date Received 2023-01-24
9 Table 1 ¨ Results of Stability test Blend Water Theoretical Viable Cell Counts (cfu/g) Activity at Formulation the time of viable cell 1=0 (Initial) T=lmonth T=3month T=6month preparation counts based 3/21/21 4/19/21 6/21/21 9/17/21 on the CoA of probiotics bulk A) Floradapt 0.048 @ 10.2E+10 1.30E+10 1.20E+10 7.40E+09 5.20E+09 Cardio 25*C 92% 57% 40%
+ MCC (control) B) Floradapt 0.093 @ 10.2E+10 1.40E+10 2.20E+10 9.40E+09 4.50E+09 Cardio 25'C 157% 67% 32%
+ Phytosterols + MCC
C) Floradapt 0.124 @ 10.1E+10 2.00E+10 4.20E+10 5.70E+10 5.00E+09 Cardio 25 C 210% 285% 25%
+ Phytosterols + Ashwagandha + MCC
Date Recue/Date Received 2023-01-24
+ MCC (control) B) Floradapt 0.093 @ 10.2E+10 1.40E+10 2.20E+10 9.40E+09 4.50E+09 Cardio 25'C 157% 67% 32%
+ Phytosterols + MCC
C) Floradapt 0.124 @ 10.1E+10 2.00E+10 4.20E+10 5.70E+10 5.00E+09 Cardio 25 C 210% 285% 25%
+ Phytosterols + Ashwagandha + MCC
Date Recue/Date Received 2023-01-24
Claims (13)
1. A long-term storage stable composition comprising:
10%-70% Lactobacillus, selected from the group consisting of: Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
2%-86% plant sterols; and 4%-88% Ashwagandha root powder.
10%-70% Lactobacillus, selected from the group consisting of: Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
2%-86% plant sterols; and 4%-88% Ashwagandha root powder.
2. The long-term storage stable composition of claim 1 wherein the composition is storage-stable for at least 6 months.
3. The long-term storage stable composition of claim 1 or 2 wherein probiotic microorganism is a mixture of Lactobacillus plantarum and Lactobacillus reuteri.
4. The long-term storage stable composition of any one of claims 1-3 wherein the Lactobacillus plantarum is one or more of CECT 7527, CECT 7528 and CETC
7529.
7529.
5. The long-term storage stable composition of any one of claims 1-4 wherein the Lactobacillus plantarum and/or Lactobacillus reuteri is added at 1X106, 1X107, 1X108, 1X106,1X101 or more colony forming units (CFU) per gram.
6. The long-term storage stable composition of claim 5 wherein the the composition has at least 1X106 CFU per gram after 6 months.
7. The long-term storage stable composition of any one of claims 1-6 wherein the plant sterols are a mixture of p-sitosterol, campesterol and stigmasterol.
8. The long-term storage stable composition of claim 7 wherein the mixture of plant sterols is at least 35% (3-sitosterol, at least 20%
campesterol and at least 10% stigmasterol.
campesterol and at least 10% stigmasterol.
9. The long-term storage stable composition of claim 7 wherein the mixture of plant sterols is at least 40% 13-sitosterol, at least 26%
campesterol and at least 18% stigmasterol.
campesterol and at least 18% stigmasterol.
10. The long-term storage stable composition of claim 1 wherein the storage-stable composition comprises 10-25% Lactobacillus, selected from the group consisting of: Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof;
50-86% plant sterols; and 4-20% Ashwagandha root powder.
50-86% plant sterols; and 4-20% Ashwagandha root powder.
11. The long-term storage stable composition of claim 1 wherein the storage-stable composition comprises (a) 50-125 mg Lactobacillus; (b) 20-100 mg Ashwagandha root powder; and (c) 250-425 mg plant sterols.
12. The long-term storage stable composition of claim 1 wherein the storage-stable composition comprises (a) 100 mg Lactobacillus plantarum, Lactobacillus reuteri or mixtures thereof; (b) 50 mg Ashwagandha root powder; and (c) 370 mg plant sterols.
13. Use of the composition of any one of claims 1-12 for treating, reducing the severity of or ameliorating hypercholesterolemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263322431P | 2022-03-22 | 2022-03-22 | |
US63322431 | 2022-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3188019A1 true CA3188019A1 (en) | 2023-09-22 |
Family
ID=88069118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3188019A Pending CA3188019A1 (en) | 2022-03-22 | 2023-01-24 | Cardiovascular health-promoting composition |
Country Status (2)
Country | Link |
---|---|
US (1) | US20230302070A1 (en) |
CA (1) | CA3188019A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094862A1 (en) * | 2004-03-23 | 2005-10-13 | Lifeline Nutraceuticals Corporation | Compositions and method for alleviating inflammation and oxidative stress in a mammal |
US20060093592A1 (en) * | 2004-10-04 | 2006-05-04 | Nutracea | Synbiotics |
EP2311473A1 (en) * | 2009-10-09 | 2011-04-20 | AB-Biotics Producciones Industriales De Microbiotas, S.L. | Lactobacillus plantarum strains as probiotics |
-
2023
- 2023-01-24 US US18/158,543 patent/US20230302070A1/en active Pending
- 2023-01-24 CA CA3188019A patent/CA3188019A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230302070A1 (en) | 2023-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lieske et al. | Use of a probioitic to decrease enteric hyperoxaluria | |
DE502007010071C5 (en) | USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL | |
US8853269B2 (en) | Composition and method for treating infections and promoting intestinal health | |
WO2019136416A1 (en) | Compositions and methods for cholesterol, glucose, and microbiome control | |
EP3064200A1 (en) | Composition comprising natural substances and/or extracts | |
CN110693916B (en) | Application of blautia in preparation of product for enhancing efficacy of hypolipidemic drug for treating hyperlipidemia | |
US6086886A (en) | Composition for promoting intestinal health | |
WO2008115574A1 (en) | Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same | |
CA3188019A1 (en) | Cardiovascular health-promoting composition | |
US20190321419A1 (en) | Composition | |
Cicero et al. | Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription? | |
US20050182037A1 (en) | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof | |
Willers et al. | The combination of a high-protein formula diet and polyglucosamine decreases body weight and parameters of glucose and lipid metabolism in overweight and obese men and women | |
WO2014015462A1 (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
CN114585380A (en) | Gastrointestinal health composition | |
DE102015114857A1 (en) | Beverage containing a pharmaceutical composition | |
WO2023237674A1 (en) | Vitamin b2 for use in improving gut health | |
CN112656887B (en) | Traditional Chinese medicine composition with anti-inflammatory and antioxidant functions, preparation and preparation method thereof | |
KR20090027383A (en) | Composition for preventing or treating hyperlipidemia | |
WO2022125667A1 (en) | Compositions having the ability to promote healthy cholesterol levels | |
WO2023237672A1 (en) | Vitamin b1 for use in improving gut health | |
Lucius | Nutritional and Botanical Approaches for Inflammatory Bowel Disease | |
WO2023237675A1 (en) | Vitamin b2 for use in improving gut health | |
Roth et al. | Efficacy and Safety of Fixed-Dose Rosuvastatin/Fenofibric Acid Versus Simvastatin Monotherapy in Patients with Elevated Low-Density Lipoprotein Cholesterol and Triglycerides | |
WO2018073794A1 (en) | A composition comprising an extract of irvingia gabonensis and strains of bifidobacteria for regulating and reducing body weight |